Cerebrolysin common uses, half-life, side effects and more

Cerebrolysin is a liquid medicine made from pig brain proteins that are broken down into a mixture of small peptides and free amino acids. It is given by injection or infusion. It is an approved prescription drug in dozens of countries for recovery after stroke, traumatic brain injury, and dementia. Outside those countries people also use it off-label as a nootropic for memory, focus, and mental recovery. It is not approved by the US Food and Drug Administration. It is bought in the United States through gray-market imports with a real risk of counterfeit product.

• Recovery after acute ischemic or hemorrhagic stroke
• Traumatic brain injury and concussion recovery
• Vascular dementia and Alzheimer's disease where it is approved
• Off-label nootropic use for memory, focus, and mental recovery

Once daily during a 10 to 20 day course repeated after a break of weeks to months

Cerebrolysin is dosed by volume of a ready-made solution at 215.2 mg per mL and injected intravenously or intramuscularly. Labeled ranges are 5 to 30 mL a day for dementia and 10 to 50 mL a day for acute stroke or traumatic brain injury. These doses are given once daily for a 10 to 20 day course. Intramuscular injection is capped at about 5 mL. Any larger single dose is given intravenously. Doses above 10 mL are given as a slow infusion diluted in saline. The maximum single dose is 50 mL. Off-label nootropic use is much lower at about 5 to 10 mL a day given intramuscularly or subcutaneously in short cycles.

• A dose above 10 mL is diluted in at least 100 mL of saline and infused slowly over 15 to 60 minutes
• Do not mix it in the same infusion or syringe with amino-acid solutions, lipid emulsions, or other drugs
• Flush the intravenous line with saline before and after giving the dose
• Subcutaneous injection is an off-label community route used only for small daily volumes and is not how the drug is given clinically

Cerebrolysin has no single plasma half-life because it is a mixture of many peptides and amino acids. The manufacturer states that standard pharmacokinetic analysis of its components is not possible. The half-life numbers on vendor pages are not based on any human study.

Cerebrolysin is a ready-made solution in single-use ampules stored at room temperature below 25°C. Keep it in the carton to protect it from light and do not freeze it. Use only a clear solution. Use an opened ampule at once and discard the remainder.

• Dizziness, headache, sweating, and nausea are the most commonly reported effects and are usually mild and short-lived
• Injection-site redness, itching, or burning
• Flushing, sweating, dizziness, and a faster or irregular heartbeat when it is injected too quickly
• Restlessness or trouble sleeping when dosed late in the day

The small peptides in Cerebrolysin are thought to mimic the body's own nerve growth factors such as BDNF and NGF. Laboratory and animal studies link this to better survival of neurons, more synaptic connections, and some protection against the cell damage that follows a stroke or injury. No single active ingredient has been identified. The effects are attributed to the whole mixture. This neurotrophic action is a proposed model rather than a proven one.

Cerebrolysin has real clinical trials. The evidence itself is mixed and mostly low quality. Positive trials exist for stroke motor recovery, traumatic brain injury, Alzheimer's disease, and vascular dementia. Most were funded by the manufacturer and run in Eastern Europe, Russia, and Asia. The single largest stroke trial enrolled about 1,070 patients and found no benefit on its main outcome. A 2023 Cochrane review of stroke found it probably makes little or no difference to survival and reported more non-fatal serious adverse events. It did not support routine use. A 2019 Cochrane review in vascular dementia rated all of the evidence as very low certainty with a high risk of bias. The proposed mechanism rests largely on research connected to the manufacturer.

• Not FDA-approved and sold in the United States only through gray-market imports where identity, purity, and sterility are unverified and counterfeits exist
• Serious allergic reactions up to life-threatening anaphylaxis have been reported and need emergency care
• The source material is pig brain tissue so it does not suit people with a pork allergy or religious limits on pork
• It carries a theoretical prion risk from its pig-tissue source that has never been documented
• Status epilepticus rules it out and epilepsy calls for caution because it can increase seizure frequency in susceptible people
• Severe kidney impairment rules it out and its safety in pregnancy or breastfeeding is not established
• It adds to the effects of antidepressants and MAO inhibitors and can raise blood pressure when a high dose is combined with an MAO inhibitor